Listening now
They looking at V being beneficial for Covid-19 patients. If they expound on this look tf out.
*1 $150M in new total rev. Over 100% higher than Q1/19
Talking about the Patent now and the road AMRN took to get V up and running.
Appeal this Summer.
New lead council.
Due to low cost, its unlikely that generics could off their version at a much cheaper cost than AMRN.
^^^^And they'll still have to wait for the FDA to approve their version of V.
More ins. coverage. Preferred brand status.
***They are def looking into V possible impact on Covid-19 Patients. When they know, they will let us know.***
The manufacturing of Vascepa is not easy, due to purity, stability, encapsulation, and packaging. The product was tested for 4 years in capsule form. Any potential manufacturer will need to overcome these obstacles. It is also time consuming and expensive. If generics don't have capacity currently, which we believe they don't, it will be expensive and take years to accomplish.
Multi-billion dollar opportunity outside the US. China clinical trial will NOT be impacted by Covid. Europe still being evaluated. Net price in Vascepa in Europe should be just as high as in the US. Regarding partnering:
waited to advance discussions until after regulatory submission. They've received questions... in early stages of reviewing potential partners! Informed by regulatory process to have 10-20 years of exclusivity. They believe it is best to see what proposals for partnering as presented... most likely Q3 of this yea
They looking at V being beneficial for Covid-19 patients. If they expound on this look tf out.
*1 $150M in new total rev. Over 100% higher than Q1/19
Talking about the Patent now and the road AMRN took to get V up and running.
Appeal this Summer.
New lead council.
Due to low cost, its unlikely that generics could off their version at a much cheaper cost than AMRN.
^^^^And they'll still have to wait for the FDA to approve their version of V.
More ins. coverage. Preferred brand status.
***They are def looking into V possible impact on Covid-19 Patients. When they know, they will let us know.***
The manufacturing of Vascepa is not easy, due to purity, stability, encapsulation, and packaging. The product was tested for 4 years in capsule form. Any potential manufacturer will need to overcome these obstacles. It is also time consuming and expensive. If generics don't have capacity currently, which we believe they don't, it will be expensive and take years to accomplish.
Multi-billion dollar opportunity outside the US. China clinical trial will NOT be impacted by Covid. Europe still being evaluated. Net price in Vascepa in Europe should be just as high as in the US. Regarding partnering:
waited to advance discussions until after regulatory submission. They've received questions... in early stages of reviewing potential partners! Informed by regulatory process to have 10-20 years of exclusivity. They believe it is best to see what proposals for partnering as presented... most likely Q3 of this yea
Last edited:
